MA42656A - Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine - Google Patents

Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine

Info

Publication number
MA42656A
MA42656A MA042656A MA42656A MA42656A MA 42656 A MA42656 A MA 42656A MA 042656 A MA042656 A MA 042656A MA 42656 A MA42656 A MA 42656A MA 42656 A MA42656 A MA 42656A
Authority
MA
Morocco
Prior art keywords
prevention
treatment
influenza virus
live attenuated
vaccine containing
Prior art date
Application number
MA042656A
Other languages
English (en)
Inventor
Luis Martinez-Sobrido
Aitor Nogales-Gonzalez
Colin Parrish
Original Assignee
Univ Cornell
Univ Rochester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Cornell, Univ Rochester filed Critical Univ Cornell
Publication of MA42656A publication Critical patent/MA42656A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA042656A 2015-08-20 2016-08-19 Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine MA42656A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562207571P 2015-08-20 2015-08-20

Publications (1)

Publication Number Publication Date
MA42656A true MA42656A (fr) 2018-06-27

Family

ID=56801864

Family Applications (1)

Application Number Title Priority Date Filing Date
MA042656A MA42656A (fr) 2015-08-20 2016-08-19 Vaccin vivant atténué comprenant des mutations de polymérase virale pour le traitement et la prévention de virus de la grippe canine

Country Status (6)

Country Link
US (2) US10478489B2 (fr)
EP (1) EP3337504A1 (fr)
AU (1) AU2016308917A1 (fr)
CA (1) CA2995382A1 (fr)
MA (1) MA42656A (fr)
WO (1) WO2017031404A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2995382A1 (fr) * 2015-08-20 2017-02-23 University Of Rochester Vaccin vivant attenue comprenant des mutations de polymerase virale pour le traitement et la prevention de virus de la grippe canine
WO2017031408A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus à cycle unique pour le développement de vaccins contre la grippe canine
US10973903B2 (en) 2015-08-20 2021-04-13 University Of Rochester NS1 truncated virus for the development of canine influenza vaccines
BR112018074910A2 (pt) 2016-06-03 2019-03-12 University Of Rochester composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito
AR114410A1 (es) 2018-02-27 2020-09-02 Univ Rochester Vacuna multivalente contra influenza viva atenuada para prevenir y controlar el virus influenza equino (vie) en caballos
CN113173976B (zh) * 2021-06-03 2022-07-12 北京市农林科学院 一种犬流感病毒h3亚型ha蛋白、其制备方法和应用
WO2026037537A1 (fr) * 2024-08-16 2026-02-19 Intervet International B.V. Vaccin contre le virus de la grippe canine

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166057A (en) 1989-08-28 1992-11-24 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand rna virus expression-systems
US5854037A (en) 1989-08-28 1998-12-29 The Mount Sinai School Of Medicine Of The City University Of New York Recombinant negative strand RNA virus expression systems and vaccines
DK0702085T4 (da) 1994-07-18 2010-04-06 Conzelmann Karl Klaus Prof Dr Rekombinant infektiøs ikke-segmenteret negativ-strenget RNA-virus
US7153510B1 (en) 1995-05-04 2006-12-26 Yale University Recombinant vesiculoviruses and their uses
EP0780475B2 (fr) 1995-08-09 2006-07-19 SCHWEIZ. SERUM- & IMPFINSTITUT BERN Procédé pour la production des virus à ARN brin-négatifs infectieux
US6264957B1 (en) 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences
EP0912724B1 (fr) 1996-07-15 2009-12-09 The Government of The United States of America, as represented by The Department of Health and Human Services Production de vaccins a base de virus respiratoire syncytial attenue, a partir de sequences nucleotidiques clonees
WO1998013501A2 (fr) 1996-09-27 1998-04-02 American Cyanamid Company Region promotrice 3' du genome et mutations du gene polymerase responsables de l'attenuation dans des virus de l'ordre appele mononegavirales
DE69842165D1 (de) 1997-05-23 2011-04-21 Us Of America As Represented By The Secretary Of The Dept Of Health And Human Services Herstellung attenuierter parainfluenza-virus impfstoffe aus klonierten nukleotidsequenzen
DE69837764T2 (de) 1997-07-11 2008-01-31 Yale University, New Haven Rhabdovirus mit gentechnisch veränderter hülle
KR20010030630A (ko) 1997-09-19 2001-04-16 윌리암 에이취 캘넌, 에곤 이 버그 약독화 호흡 신시티아 바이러스
US7959929B2 (en) 2005-04-21 2011-06-14 University Of Florida Research Foundation, Inc. Materials and methods for respiratory disease control in canines
US7425336B2 (en) 2005-08-25 2008-09-16 Mevial Limited Canine influenza vaccines
WO2007042884A1 (fr) 2005-10-07 2007-04-19 Pfizer Products Inc. Vaccins et methodes permettant de traiter la grippe canine
KR100850545B1 (ko) 2007-10-30 2008-08-05 주식회사 에니멀제네틱스 신규한 개 인플루엔자 바이러스 및 이의 백신
US8475807B2 (en) * 2008-03-13 2013-07-02 University Of Maryland College Park Avian influenza virus live attenuated vaccine and uses thereof
US20120269849A1 (en) 2009-10-09 2012-10-25 Eckard Wimmer Attenuated influenza viruses and vaccines
EP2751260A2 (fr) 2011-09-02 2014-07-09 Westfälische Wilhelms-Universität Münster Virus grippaux vivants atténués
WO2015010073A1 (fr) 2013-07-19 2015-01-22 University Of Rochester Vaccins atténués contre la grippe et leurs utilisations
CA2995382A1 (fr) * 2015-08-20 2017-02-23 University Of Rochester Vaccin vivant attenue comprenant des mutations de polymerase virale pour le traitement et la prevention de virus de la grippe canine
WO2017031408A1 (fr) 2015-08-20 2017-02-23 University Of Rochester Virus à cycle unique pour le développement de vaccins contre la grippe canine
BR112018074910A2 (pt) 2016-06-03 2019-03-12 University Of Rochester composição imunológica, e, método de indução de uma resposta imunológica contra o vírus da influenza equina em um sujeito

Also Published As

Publication number Publication date
CA2995382A1 (fr) 2017-02-23
WO2017031404A1 (fr) 2017-02-23
US20200023055A1 (en) 2020-01-23
US20180243401A1 (en) 2018-08-30
AU2016308917A1 (en) 2018-03-15
US10478489B2 (en) 2019-11-19
EP3337504A1 (fr) 2018-06-27
US11065326B2 (en) 2021-07-20

Similar Documents

Publication Publication Date Title
HUS2200053I1 (hu) HIV vírusfertõzés megelõzõ vagy terápiás kezelésére alkalmas terápiás vegyületek
MA50335A (fr) Vaccins à acide nucléique contre des virus respiratoires
HUE052856T2 (hu) Eljárások és gyógyászati készítmények Hepatitis B vírus fertõzés kezelésére
CL2017000064A1 (es) Vacunas contra virus influenza y usos de las mismas
HUE071243T2 (hu) Mikro-disztrofin bejuttatása adeno-asszociált vírus vektorral izomdisztrófia kezelésére
PH12017500949A1 (en) Human antibodies to influenza hemagglutinin
PH12017500207B1 (en) Indoles for use in influenza virus infection
ZA202003155B (en) Liquid vaccines of live enveloped viruses
EP3233878A4 (fr) Phosphoramidates pour le traitement du virus de l'hépatite b
PL3346995T3 (pl) Kompozycje terapeutyczne do leczenia ludzkiego wirusa niedoboru odporności
EP3697915A4 (fr) Administration par vecteur à virus adéno-associé de micro-dystrophine spécifique de muscles pour traiter la dystrophie musculaire
EP3463447A4 (fr) Régimes de vaccination contre le virus de la grippe
CL2017000063A1 (es) Vacunas contra virus influenza y usos de las mismas
EP3484511A4 (fr) Compositions vaccinales pour le traitement d'une infection par le virus zika
LT3197489T (lt) Būdai ir kompozicijos, skirti indukuoti apsauginį imunitetą prieš žmogaus imunodeficito viruso infekciją
EP3509596C0 (fr) Norketotifen pour le traitement de l'hypercytokinémie et l'infection virale
HUE045906T2 (hu) Új szulfonimidoilpurinon vegyületek és származékok vírusfertõzés kezelésére és megelõzésére
MX380393B (es) Vectores atenuados de influenza para la prevencion y/o tratamiento de enfermedades infecciosas y para el tratamiento de enfermedades oncologicas.
BR112014025339A2 (pt) Método para tratamento ou prevenção ou redução de infecção do virus influenza e composição farmacêutica para o mesmo
EP3370723A4 (fr) Traitement d'une infection par le virus de l'hépatite delta
EP3403671A4 (fr) Vaccin contenant des particules virales immobilisées
PT3137078T (pt) Tratamento da infeção por vírus da hepatite delta
EP3317290A4 (fr) Compositions et méthodes de traitement d'une infection virale
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
EP3303370A4 (fr) Produits de construction t20 pour thérapie et/ou vaccins anti-vih (virus de l'immunodéficience humaine)